Bayer’s Aliqopa gets speedy review for marginal zone lymphoma

Bayer’s Aliqopa gets speedy review for marginal zone lymphoma

Source: 
Pharmaforum
snippet: 

The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) patients who have received two prior therapies.